All News
The RheumNow Week in Review – Vitamin D Snark Report (4.20.18)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. A second life for Syk kinase, Vitamin D talk, VTE, regulatory hearings and the Lupus clinic edge.
Read ArticleKineret Approved for Still's Disease in EU
SOBI has announced that Kineret (anakinra) has been approved by the European Commission (EC) for the treatment of Still’s disease (Systemic Juvenile Idiopathic Arthritis [SJIA] and Adult-Onset Still’s Disease [AOSD]), in all 28 European Union (EU) member states.
Read ArticleRheumNow Week in Review - Do you Dig Shingrix? (4.6.2018)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlights includes manpower shortfalls, comorbidities in AA Lupus, certolizumab pregnancy safety, which Shingles vaccine is best and the power of combination biologics in severe refractory SLE.
Read ArticleUveitis in JIA: Screen All, Treat Early
A European group of experts has formulated consensus-based recommendations for the treatment of juvenile idiopathic arthritis (JIA)-associated uveitis, focusing on screening, monitoring, and treatment of this potentially devastating extra-articular manifestation of JIA.
Read ArticleIL-6 Inhibition Most Effective in Polycyclic Systemic JIA
The German Autoinflammatory Disease (AID) registry has studied the effects of the IL-6 inhibitor tocilizumab (TCZ) in systemic juvenile idiopathic arthritis (sJIA) patients and shown a clinical response rate of 35% during the first 12 weeks, and inactive disease and/or remission (with medication)
Read ArticleThe RheumNow Week in Review -30 March 2018
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. News on drug regulatory decisions, fenofibrate and gout, Still's disease, TB and infection rates, SpA and hidradenitis suppurativa, and predicting methotrexate non-responders.
Read ArticleAbatacept Efficacy in JIA
Subcutaneous abatacept (Orencia) showed efficacy among children with polyarticular juvenile idiopathic arthritis (JIA) in an open-label phase III trial.
Read ArticleIL-18 Binding Protein Effective in Adult-Onset Still's Disease
Gabay and colleagues have reported the results of a novel new recombinant human IL-18 binding protein, tadekinig alfa, demonstrating its effectiveness in an open-label dose escalating study in patients with adult-onset Still's disease (AOSD).
Read ArticlePediatric Use of TNF inhbitors Does Not Increase Malignancy Risk
A study of USA administrative claims data between 2000 to 2014 assessed the risk of cancer with exposure to tumour necrosis factor inhibitor (TNFi) in pediatric patients and found that TNFi therapy did not significantly increase the risk compared those not receiving TNFi.
Read ArticleRWCS Day 4 Podcast
Listen in on the proceedings from the 2018 RWCS meeting in Maui, with excerpts from leading teachers in rheumatology. This podcast features presentations from Drs.
Read ArticleRecurrent Uveitis Increases the Risk of Ankylosing Spondylitis
Arthritis Research and Therapy reports on the epidemiologic association between recurrent anterior uveitis and ankylosing spondylitis (AS) noting that as the number of uveitis episodes increases, so does the incidence of AS.
Read ArticleRWCS Day 1 Podcast
Listen in on the proceedings from RWCS with excerpts from leading teachers in rheumatology. This podcast features Drs. Bevra Hahn, Artie Kavanaugh and Anne Stevens.
Read ArticleThe RheumNow Week in Review - 2 February 2018
Dr. Jack Cush reviews highlights, news and recent research published this week on RheumNow.com. This week's report includes rising epidemiologic numbers, vaccine updates for H.
Read ArticleThe RheumNow Week in Review - 26 January 2018
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report covers the price of biologics treatment in psoriasis, comorbidities in myositis, bronchiectasis with MPO antibodies, and the risk of secondary TNF failure with anti-drug antibodies.
Read ArticleIL-1 and IL-6 Inhibition Preferred in Systemic JIA
Since 2000, the German Biologics register (BiKeR) has prospectively enrolled children with juvenile idiopathic arthritis to assess outcomes with biologic therapies. A new report evaluates the efficacy and safety of etanercept (ETA), tocilizumab (TOC) and the interleukin-1 inhibitors (anakin
Read ArticleThe RheumNow Week in Review - 22 December 2017
Dr. Jack Cush reviews highlights and news from the past week on RheumNow.com.
Read ArticleThe RheumNow Week in Review - 15 December 2017
Dr. Jack Cush reviews the news from the past week on RheumNow.com. Subscribe to the podcast on iTunes and SoundCloud.com.
Read ArticleOffspring of RA Women Have Higher Risk of RA and Other Diseases
Despite a growing body of evidence suggesting that maternal health is more important than maternal medications to fetal and infant outcomes, little is known about the long term oucomes of infants born to mothers with rheumatoid arthritis (RA). Using Danish population data, researchers have shown in utero exposure to maternal RA is associated with an increased risk of thyroid disease, and an increased risk of future RA.
Read ArticleWhy TNF Inhibitors May Work in Some Autoinflammatory Patients
The NLRP3 inflammasome is a critical component of the innate immune system and activation of NLRP3 inflammasome results in caspase-1–dependent secretion of the proinflammatory cytokines IL-1β and IL-18.
Read ArticleThe RheumNow Week in Review - 8 December 2017
Dr. Jack Cush covers the news and journal articles published on RheumNow.comin the past week.
Read Article